Clarisse Kerleau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Clarisse Kerleau has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Sophie Brouard
Inserm, Nantes Université, CHU de Nantes, Center for Research in Transplantation and Translational Immunology CR2TI, UMR 1064, ITUN, Nantes, France
7 shared publications - Luc Colas
Plateforme Transversale d'Allergologie et d'Immunologie Clinique, Institut du Thorax, CHU de Nantes, Nantes, France
4 shared publications - Magali Giral
CR2TI, UMR 1064, Inserm, Université de Nantes, ITUN, CHU Nantes, Nantes, France
4 shared publications - Richard Danger
Center for Research in Transplantation and Translational Immunology, UMR 10, Nantes Université, INSERM, Nantes, France
4 shared publications - Christophe Masset
Institut de Transplantation-Urologie-Néphrologie (ITUN), Nantes University Hospital, Nantes, France; Center for Research in Transplantation and Translational Immunology, INSERM UMR 1064, Nantes University, Nantes, France
3 shared publications - Magali Giral
CHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, ITUN, 44000 Nantes, France
3 shared publications
Latest Publications
- Open Access
- 27 January 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (6) , 1251-1261
IgA-Producing B Cells Exert Regulatory Function through Granzyme B in Kidney Allograft Tolerance
Key Points: Tolerant patients of kidney graft exhibit higher IgA production than other kidney transplanted patients without modification for IgG. IgA-expressing B cells from tolerant patients expressed granzyme B and exert regulatory functions through granzyme B production. Background: Tolerant kidney transplant recipients without immunosuppression have a high frequency of circulating granzyme B (GZMB)–expressing regulatory B cells (Breg). Because the precursors of these Bregs remain unknown and IgA-secreting B cells have been shown to have regulatory properties in different situations, we investigated the association between IgA- and GZMB-expressing B cells in a case-control study. Methods: Forty-five healthy volunteers and 31 kidney transplant recipients with either stable graft function under immunosuppression ( n =10), antibody-mediated rejection ( n =7), or tolerant patients (TOL; n =14) were included. Serum immunoglobulin concentrations as glycosylation were measured by ELISA; forms of IgA were examined by Western blot. Bregs were analyzed by single-cell RNA sequencing and multiparameter spectral flow cytometry. Their function was assessed in cocultured with T cells. Results: Serum IgA concentration was elevated in TOL compared with other transplanted patients, especially the noninflammatory IgA1 subclass, without changes in IgA size or glycosylation. Single-cell transcriptomic analysis revealed higher IgA gene expression in GZMB expressing B cells and conversely higher GZMB gene expression in IgA-expressing B cells. Phenotyping analysis by spectral multiparameter flow cytometry showed that IgA+ B cells were memory B cells, and that IgA+ B cells from TOL tended to express more GZMB compared with antibody-mediated rejection patients. In functional assays, IgA+ B cells exhibited high regulatory functions that were partially prevented by the presence of GZMB inhibitor. Conclusions: These data show a strong association between IgA+ and GZMB+ Bregs, particularly in tolerant kidney transplant recipients with higher GZMB and IgA expression and greater suppressive properties. Clinical Trial registry name and registration number: NCT02900040.
- 27 January 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (6) , 1251-1261
Open AccessIgA-Producing B Cells Exert Regulatory Function through Granzyme B in Kidney Allograft Tolerance
Key Points: Tolerant patients of kidney graft exhibit higher IgA production than other kidney transplanted patients without modification for IgG. IgA-expressing B cells from tolerant patients expressed granzyme B and exert regulatory functions through granzyme B production. Background: Tolerant kidney transplant recipients without immunosuppression have a high frequency of circulating granzyme B (GZMB)–expressing regulatory B cells (Breg). Because the precursors of these Bregs remain unknown and IgA-secreting B cells have been shown to have regulatory properties in different situations, we investigated the association between IgA- and GZMB-expressing B cells in a case-control study. Methods: Forty-five healthy volunteers and 31 kidney transplant recipients with either stable graft function under immunosuppression ( n =10), antibody-mediated rejection ( n =7), or tolerant patients (TOL; n =14) were included. Serum immunoglobulin concentrations as glycosylation were measured by ELISA; forms of IgA were examined by Western blot. Bregs were analyzed by single-cell RNA sequencing and multiparameter spectral flow cytometry. Their function was assessed in cocultured with T cells. Results: Serum IgA concentration was elevated in TOL compared with other transplanted patients, especially the noninflammatory IgA1 subclass, without changes in IgA size or glycosylation. Single-cell transcriptomic analysis revealed higher IgA gene expression in GZMB expressing B cells and conversely higher GZMB gene expression in IgA-expressing B cells. Phenotyping analysis by spectral multiparameter flow cytometry showed that IgA+ B cells were memory B cells, and that IgA+ B cells from TOL tended to express more GZMB compared with antibody-mediated rejection patients. In functional assays, IgA+ B cells exhibited high regulatory functions that were partially prevented by the presence of GZMB inhibitor. Conclusions: These data show a strong association between IgA+ and GZMB+ Bregs, particularly in tolerant kidney transplant recipients with higher GZMB and IgA expression and greater suppressive properties. Clinical Trial registry name and registration number: NCT02900040.
- Open Access
Peripheral transcriptomic signature of chronic antibody-mediated rejection in kidney transplantation: a dual effect for MMP9 over time
BACKGROUND: Chronic antibody-mediated rejection (CAMR) is the main cause of late kidney allograft loss, and no specific effective treatment has been identified so far. Here, we proposed to explore the non-invasive peripheral blood transcriptome signature of CAMR. METHODS: First, we compared PBMC gene expression from bulk RNA-seq between 35 patients experiencing late CAMR (mean=7.1 years) vs. 43 patients without graft dysfunction at late stages (Stable, mean=4.4 years) to identify the molecular drivers of CAMR. Second, we explored the 1-year gene expression signature in stable patients exhibiting (n=11) or not (n=51) a subsequent CAMR to define possible predictive biomarkers of CAMR. RESULTS: We reported 188 differentially regulated genes during late CAMR (qe.g. MMP9 , MMP8 and LCN2 ) and from the C1q complement complex ( e.g. C1QA , C1QB and C1QC ), as well as with a downregulation of genes associated with subclinical rejection ( e.g. TCL1A ). The upregulated degranulation and complement signatures were validated in six independent cohorts gathering a total of 360 stable and 131 chronic rejection patients. Contrary to the injury effect observed during late stages, MMP9 was downregulated at 1-year in PBMCs of patients who later experienced CAMR. CONCLUSIONS: These results suggest a dual role for MMP9 expression with an early protective effect against CAMR and deleterious effects in the later stage. MMP9 peripheral expression appears as a promising biomarker candidate for kidney transplantation follow-up. Translational Statement: CAMR is the main cause of late kidney allograft loss, and we aimed to identify molecular targets and biomarkers. By comparing CAMR and stable kidney-transplanted patients prior and during diagnosis, we identified MMP9 as a potential biomarker for both CAMR prognosis and diagnosis. We also highlighted the C1q complement complex and TCL1A in CAMR as potential diagnostic biomarkers. These results provide new insights into CAMR pathophysiology and may guide the development of innovative treatment targeting MMP9 expression in kidney transplanted patients. Ultimately, this work laid the foundation for exploring MMP9 expression kinetics and develop new ways of treating CAMR patients.
Open AccessPeripheral transcriptomic signature of chronic antibody-mediated rejection in kidney transplantation: a dual effect for MMP9 over time
BACKGROUND: Chronic antibody-mediated rejection (CAMR) is the main cause of late kidney allograft loss, and no specific effective treatment has been identified so far. Here, we proposed to explore the non-invasive peripheral blood transcriptome signature of CAMR. METHODS: First, we compared PBMC gene expression from bulk RNA-seq between 35 patients experiencing late CAMR (mean=7.1 years) vs. 43 patients without graft dysfunction at late stages (Stable, mean=4.4 years) to identify the molecular drivers of CAMR. Second, we explored the 1-year gene expression signature in stable patients exhibiting (n=11) or not (n=51) a subsequent CAMR to define possible predictive biomarkers of CAMR. RESULTS: We reported 188 differentially regulated genes during late CAMR (qe.g. MMP9 , MMP8 and LCN2 ) and from the C1q complement complex ( e.g. C1QA , C1QB and C1QC ), as well as with a downregulation of genes associated with subclinical rejection ( e.g. TCL1A ). The upregulated degranulation and complement signatures were validated in six independent cohorts gathering a total of 360 stable and 131 chronic rejection patients. Contrary to the injury effect observed during late stages, MMP9 was downregulated at 1-year in PBMCs of patients who later experienced CAMR. CONCLUSIONS: These results suggest a dual role for MMP9 expression with an early protective effect against CAMR and deleterious effects in the later stage. MMP9 peripheral expression appears as a promising biomarker candidate for kidney transplantation follow-up. Translational Statement: CAMR is the main cause of late kidney allograft loss, and we aimed to identify molecular targets and biomarkers. By comparing CAMR and stable kidney-transplanted patients prior and during diagnosis, we identified MMP9 as a potential biomarker for both CAMR prognosis and diagnosis. We also highlighted the C1q complement complex and TCL1A in CAMR as potential diagnostic biomarkers. These results provide new insights into CAMR pathophysiology and may guide the development of innovative treatment targeting MMP9 expression in kidney transplanted patients. Ultimately, this work laid the foundation for exploring MMP9 expression kinetics and develop new ways of treating CAMR patients.
- 5 September 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (2) , 322-339
Evolving landscape of thrombotic microangiopathy in kidney transplant recipients in the post–C5 inhibitor era
- 5 September 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (2) , 322-339
Evolving landscape of thrombotic microangiopathy in kidney transplant recipients in the post–C5 inhibitor era
- Open Access
- 7 November 2024
- Published by Wiley in European Journal of Immunology
- Vol. 54 (12) , e2451143
Rise of a CD27− IgD− CD11c+ B cells population in kidney recipients achieving long‐term graft stability under immunosuppression
The use of immunosuppressive treatment is required to prevent rejection events, even a long time after kidney transplantation despite rare recipients achieving long‐term graft stability without the need for immunosuppressive treatment, called operationally tolerant patients (TOLs). We comprehensively investigate the immune system of long‐term IS recipients (LTTs) and TOLs to highlight their shared and unique immune features. Blood immune cell phenotyping was performed by spectral cytometry. Samples from 34 individuals were analyzed, including 6 LTTs, 8 TOLs, 10 stable patients at 1 year posttransplantation (STAs), and 10 healthy volunteers. B cells differed between LTTs and TOLs with a decreased total B‐cell frequency and the acquisition of a memory phenotype in LTTs whereas a naive phenotype is maintained in TOLs. The frequencies of IgD−CD27− B cells and CD11c+ memory B cells are increased in LTTs, with an exhausted phenotype, evoked by a significant decrease in CD25 expression. These CD11c+ B cells display an exhausted phenotype similar to those found in several chronic immune diseases in which they have been shown to participate in their pathophysiology, suggesting active chronic inflammation in LTTs. Altogether, these data indicate that precautions should be taken to minimize IS use.
- 7 November 2024
- Published by Wiley in European Journal of Immunology
- Vol. 54 (12) , e2451143
Open AccessRise of a CD27− IgD− CD11c+ B cells population in kidney recipients achieving long‐term graft stability under immunosuppression
The use of immunosuppressive treatment is required to prevent rejection events, even a long time after kidney transplantation despite rare recipients achieving long‐term graft stability without the need for immunosuppressive treatment, called operationally tolerant patients (TOLs). We comprehensively investigate the immune system of long‐term IS recipients (LTTs) and TOLs to highlight their shared and unique immune features. Blood immune cell phenotyping was performed by spectral cytometry. Samples from 34 individuals were analyzed, including 6 LTTs, 8 TOLs, 10 stable patients at 1 year posttransplantation (STAs), and 10 healthy volunteers. B cells differed between LTTs and TOLs with a decreased total B‐cell frequency and the acquisition of a memory phenotype in LTTs whereas a naive phenotype is maintained in TOLs. The frequencies of IgD−CD27− B cells and CD11c+ memory B cells are increased in LTTs, with an exhausted phenotype, evoked by a significant decrease in CD25 expression. These CD11c+ B cells display an exhausted phenotype similar to those found in several chronic immune diseases in which they have been shown to participate in their pathophysiology, suggesting active chronic inflammation in LTTs. Altogether, these data indicate that precautions should be taken to minimize IS use.
- Open Access
Regulatory B Cells Expressing Granzyme B from Tolerant Renal Transplant Patients: Highly Differentiated B Cells with a Unique Pathway with a Specific Regulatory Profile and Strong Interactions with Immune System Cells
The aim of our study was to determine whether granzyme B-expressing regulatory B cells (GZMB+ B cells) are enriched in the blood of transplant patients with renal graft tolerance. To achieve this goal, we analysed two single-cell RNA sequencing (scRNAseq) datasets: (1) peripheral blood mononuclear cells (PBMCs), including GZMB+ B cells from renal transplant patients, i.e., patients with stable graft function on conventional immunosuppressive treatment (STA, n = 3), drug-free tolerant patients (TOL, n = 3), and patients with antibody-mediated rejection (ABMR, n = 3), and (2) ex-vivo-induced GZMB+ B cells from these groups. In the patient PBMCs, we first showed that natural GZMB+ B cells were enriched in genes specific to Natural Killer (NK) cells (such as NKG7 and KLRD1) and regulatory B cells (such as GZMB, IL10, and CCL4). We performed a pseudotemporal trajectory analysis of natural GZMB+ B cells and showed that they were highly differentiated B cells with a trajectory that is very different from that of conventional memory B cells and linked to the transcription factor KLF13. By specifically analysing GZMB+ natural B cells in TOLs, we found that these cells had a very specific transcriptomic profile associated with a reduction in the expression of HLA molecules, apoptosis, and the inflammatory response (in general) in the blood and that this signature was conserved after ex vivo induction, with the induction of genes associated with migration processes, such as CCR7, CCL3, or CCL4. An analysis of receptor/ligand interactions between these GZMB+/− natural B cells and all of the immune cells present in PBMCs also demonstrated that GZMB+ B cells were the B cells that carried the most ligands and had the most interactions with other immune cells, particularly in tolerant patients. Finally, we showed that these GZMB+ B cells were able to infiltrate the graft under inflammatory conditions, thus suggesting that they can act in locations where immune events occur.
Open AccessRegulatory B Cells Expressing Granzyme B from Tolerant Renal Transplant Patients: Highly Differentiated B Cells with a Unique Pathway with a Specific Regulatory Profile and Strong Interactions with Immune System Cells
The aim of our study was to determine whether granzyme B-expressing regulatory B cells (GZMB+ B cells) are enriched in the blood of transplant patients with renal graft tolerance. To achieve this goal, we analysed two single-cell RNA sequencing (scRNAseq) datasets: (1) peripheral blood mononuclear cells (PBMCs), including GZMB+ B cells from renal transplant patients, i.e., patients with stable graft function on conventional immunosuppressive treatment (STA, n = 3), drug-free tolerant patients (TOL, n = 3), and patients with antibody-mediated rejection (ABMR, n = 3), and (2) ex-vivo-induced GZMB+ B cells from these groups. In the patient PBMCs, we first showed that natural GZMB+ B cells were enriched in genes specific to Natural Killer (NK) cells (such as NKG7 and KLRD1) and regulatory B cells (such as GZMB, IL10, and CCL4). We performed a pseudotemporal trajectory analysis of natural GZMB+ B cells and showed that they were highly differentiated B cells with a trajectory that is very different from that of conventional memory B cells and linked to the transcription factor KLF13. By specifically analysing GZMB+ natural B cells in TOLs, we found that these cells had a very specific transcriptomic profile associated with a reduction in the expression of HLA molecules, apoptosis, and the inflammatory response (in general) in the blood and that this signature was conserved after ex vivo induction, with the induction of genes associated with migration processes, such as CCR7, CCL3, or CCL4. An analysis of receptor/ligand interactions between these GZMB+/− natural B cells and all of the immune cells present in PBMCs also demonstrated that GZMB+ B cells were the B cells that carried the most ligands and had the most interactions with other immune cells, particularly in tolerant patients. Finally, we showed that these GZMB+ B cells were able to infiltrate the graft under inflammatory conditions, thus suggesting that they can act in locations where immune events occur.
- 3 February 2023
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (11) , 1291-1299
KiT-GENIE, the French genetic biobank of kidney transplantation
KiT-GENIE is a monocentric DNA biobank set up to consolidate the very rich and homogeneous DIVAT French cohort of kidney donors and recipients (D/R) in order to explore the molecular factors involved in kidney transplantation outcomes. We collected DNA samples for kidney transplantations performed in Nantes, and we leveraged GWAS genotyping data for securing high-quality genetic data with deep SNP and HLA annotations through imputations and for inferring D/R genetic ancestry. Overall, the biobank included 4217 individuals (n = 1945 D + 2,272 R, including 1969 D/R pairs), 7.4 M SNPs and over 200 clinical variables. KiT-GENIE represents an accurate snapshot of kidney transplantation clinical practice in Nantes between 2002 and 2018, with an enrichment in living kidney donors (17%) and recipients with focal segmental glomerulosclerosis (4%). Recipients were predominantly male (63%), of European ancestry (93%), with a mean age of 51yo and 86% experienced their first graft over the study period. D/R pairs were 93% from European ancestry, and 95% pairs exhibited at least one HLA allelic mismatch. The mean follow-up time was 6.7 years with a hindsight up to 25 years. Recipients experienced biopsy-proven rejection and graft loss for 16.6% and 21.3%, respectively. KiT-GENIE constitutes one of the largest kidney transplantation genetic cohorts worldwide to date. It includes homogeneous high-quality clinical and genetic data for donors and recipients, hence offering a unique opportunity to investigate immunogenetic and genetic factors, as well as donor-recipient interactions and mismatches involved in rejection, graft survival, primary disease recurrence and other comorbidities.
- 3 February 2023
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (11) , 1291-1299
KiT-GENIE, the French genetic biobank of kidney transplantation
KiT-GENIE is a monocentric DNA biobank set up to consolidate the very rich and homogeneous DIVAT French cohort of kidney donors and recipients (D/R) in order to explore the molecular factors involved in kidney transplantation outcomes. We collected DNA samples for kidney transplantations performed in Nantes, and we leveraged GWAS genotyping data for securing high-quality genetic data with deep SNP and HLA annotations through imputations and for inferring D/R genetic ancestry. Overall, the biobank included 4217 individuals (n = 1945 D + 2,272 R, including 1969 D/R pairs), 7.4 M SNPs and over 200 clinical variables. KiT-GENIE represents an accurate snapshot of kidney transplantation clinical practice in Nantes between 2002 and 2018, with an enrichment in living kidney donors (17%) and recipients with focal segmental glomerulosclerosis (4%). Recipients were predominantly male (63%), of European ancestry (93%), with a mean age of 51yo and 86% experienced their first graft over the study period. D/R pairs were 93% from European ancestry, and 95% pairs exhibited at least one HLA allelic mismatch. The mean follow-up time was 6.7 years with a hindsight up to 25 years. Recipients experienced biopsy-proven rejection and graft loss for 16.6% and 21.3%, respectively. KiT-GENIE constitutes one of the largest kidney transplantation genetic cohorts worldwide to date. It includes homogeneous high-quality clinical and genetic data for donors and recipients, hence offering a unique opportunity to investigate immunogenetic and genetic factors, as well as donor-recipient interactions and mismatches involved in rejection, graft survival, primary disease recurrence and other comorbidities.
- Open Access
Development and Validation of Multivariable Prediction Models of Serological Response to SARS-CoV-2 Vaccination in Kidney Transplant Recipients
Background: Repeated vaccination against SARS-CoV-2 increases serological response in kidney transplant recipients (KTR) with high interindividual variability. No decision support tool exists to predict SARS-CoV-2 vaccination response in KTR. Methods: We developed, internally and externally validated five different multivariable prediction models of serological response after the third and fourth vaccine dose against SARS-CoV-2 in KTR. Using 27 candidate predictor variables, we applied statistical and machine learning approaches including logistic regression (LR), LASSO-regularized LR, random forest, and gradient boosted regression trees. For development and internal validation, data from 585 vaccinations were used. External validation was performed in four independent, international validation datasets comprising 191, 184, 254, and 323 vaccinations, respectively. Findings: LASSO-regularized LR performed on the whole development dataset yielded a 23- and 11- variable model, respectively. External validation showed AUC-ROC of 0.855, 0.749, 0.828, and 0.787 for the sparser 11-variable model, yielding an overall performance 0.819. Interpretation: An 11-variable LASSO-regularized LR model predicts vaccination response in KTR with good overall accuracy. Implemented as an online tool, it can guide decisions when choosing between different immunization strategies to improve protection against COVID-19 in KTR.
Open AccessDevelopment and Validation of Multivariable Prediction Models of Serological Response to SARS-CoV-2 Vaccination in Kidney Transplant Recipients
Background: Repeated vaccination against SARS-CoV-2 increases serological response in kidney transplant recipients (KTR) with high interindividual variability. No decision support tool exists to predict SARS-CoV-2 vaccination response in KTR. Methods: We developed, internally and externally validated five different multivariable prediction models of serological response after the third and fourth vaccine dose against SARS-CoV-2 in KTR. Using 27 candidate predictor variables, we applied statistical and machine learning approaches including logistic regression (LR), LASSO-regularized LR, random forest, and gradient boosted regression trees. For development and internal validation, data from 585 vaccinations were used. External validation was performed in four independent, international validation datasets comprising 191, 184, 254, and 323 vaccinations, respectively. Findings: LASSO-regularized LR performed on the whole development dataset yielded a 23- and 11- variable model, respectively. External validation showed AUC-ROC of 0.855, 0.749, 0.828, and 0.787 for the sparser 11-variable model, yielding an overall performance 0.819. Interpretation: An 11-variable LASSO-regularized LR model predicts vaccination response in KTR with good overall accuracy. Implemented as an online tool, it can guide decisions when choosing between different immunization strategies to improve protection against COVID-19 in KTR.
- Open Access
- 28 February 2022
- Published by Elsevier in EBioMedicine
- Vol. 77, 103844
Urinary metabolomic profiling from spontaneous tolerant kidney transplanted recipients shows enrichment in tryptophan-derived metabolites
- 28 February 2022
- Published by Elsevier in EBioMedicine
- Vol. 77, 103844
Open AccessUrinary metabolomic profiling from spontaneous tolerant kidney transplanted recipients shows enrichment in tryptophan-derived metabolites